The KINETICS trial

KINETICS is a large, retrospective, real-world study that will look into the potential role of lanreotide monotherapy as first line therapy for paitents with a gastro-enteropancreatic  neuroendocrine tumor (GEP-NET). The study includes patients treated with lanreotide monotherapy between March 1st 2015 and December 31st 2022 across 7 centers in Belgium, Austria, France, Germany and Spain. Eligible patients were matched and classified in 2 cohorts: patients with a KI-67 index >10% and patients with a Ki-67 index ≤10%. Patients were also stratified according to primary tumor location (gastrointestinal vs. pancreatic). Results of KINETICS are expected by the end of 2025.